enpp/carbonicanhydrasein1

Enpp Carbonic anhydrase-IN-1 (compound 1e) is a potent inhibitor of Enpp and carbonic anhydrase, exhibiting IC50s of 1.36, 1.35, 3.00, 0.88, and 1.02 µM for NPP1, NPP2, NPP3, CA-II, and CA-IX respectively. Enpp Carbonic anhydrase-IN-1 also demonstrates selective antiproliferative activity for cancer cells.

Enpp-1-IN-16 is an inhibitor targeting ENPP1 with potential anti-cancer activity.Enpp-1-IN-16 can be used to study insulin resistance in relation to type II diabetes mellitus and various ENPP1-mediated diseases in the chondrocalcinosis and osteoarthritis classes.

Enpp-1-IN-1 is an inhibitor of Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1)

Enpp-1-IN-13 is an ectonucleotide pyrophosphatase/phosphodiesterase (ENPP) inhibitor that is able to act on ENPP1 (IC50: 1.29 μM) and ENPP3 (IC50: 20.2 μM), exhibiting anticancer effects.

Enpp-1-IN-10 (compound 1) is a potent inhibitor of Ecto-nucleotide pyrophosphatase phosphodiesterases 1 (ENPP1) with a Ki value of 3.866 μM, suitable for anticancer research [1].

Enpp-1-IN-6 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) with potential applications in cancer and infectious disease research.

Enpp-1-IN-14 is a potent inhibitor of Ectonucleotide Pyrophosphatase Phosphodiesterase-1 (ENPP1) with an IC50 value of 32.38 nM for recombinant human ENPP-1. Enpp-1-IN-14 has anti-tumor activity.

Compound 88a (Enpp-1-IN-15) is an inhibitor of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp-1), exhibiting a Ki value of 0.00586 nM [1].

Enpp-1-IN-4 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) with potential for cancer disease studies.

Enpp-1-IN-5 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1), which exhibits broad specificity, capable of cleaving phosphodiester bonds of nucleotides and nucleotides, as well as pyrophosphate bonds of nucleotides and nucleotides. Enpp-1-IN-5 has potential applications in cancer and infectious disease research.

Enpp-1-IN-9, a powerful inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP1), exhibits wide substrate specificity, capable of cleaving various bonds such as phosphodiester bonds of nucleotides and nucleotide sugars, as well as pyrophosphate bonds of nucleotides and nucleotide sugars. Its potential application lies in the fields of cancer and infectious disease research[1].

Enpp-1-IN-19 (compound 29f) is an orally active inhibitor of ENPP1 that effectively blocks cGAMP hydrolysis with an IC50 of 68 nM. It not only enhances anti-PD-L1 responses and curtails tumor growth in CT26 syngeneic models but also boosts STING-mediated type I interferon responses. Additionally, Enpp-1-IN-19 fosters immune memory and aids in preventing tumor recurrence [1].

Enpp-1-IN-7 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1), which has broad specificity and cleaves a wide range of substrates, including phosphodiester bonds and pyrophosphate bonds of nucleotides and nucleotides. Enpp-1-IN-7 has potential applications in cancer and infectious disease research.

Enpp-1-IN-17 (example 274) is a potent inhibitor of ENPP1, with inhibition constants (Ki values) ranging from 100 nM to 1 μM for cGAMP hydrolysis and greater than 1 μM for ATP hydrolysis, demonstrating a selectivity ratio of over 6.4 favoring cGAMP hydrolysis inhibition [1].

Enpp-1-IN-12 (compound 43), an orally active and potent inhibitor of ecto-nucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) with a K_i of 41 nM, exhibits anti-tumor activity [1].

Enpp-1-IN-8 is a potent ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitor with broad specificity, capable of cleaving a wide range of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds of nucleotides and nucleotide sugars. Enpp-1-IN-8 shows potential for cancer and infectious disease studies.

Enpp-1-IN-11 (compound 23) is a highly potent inhibitor of Ecto-nucleotide pyrophosphatase phosphodiesterases 1 (ENPP1), with a Ki value of 45 nM. It demonstrates excellent stability in human and mouse plasma and exhibits low clearance in both human and mouse liver microsomes, holding promise for anticancer research [1].